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Abstract
Background: Accumulating evidence has indicated the relationship between the systemic immune system and the
central nervous system including the inner ear.
Results: We have shown that age-related developments of T-cell dysfunction, hearing loss, and degeneration of
cochlear spiral ganglion (SG) neurons observed in 6-month-old mice were recovered in 12 months old mice which
previously given fetal thymus transplants twice. We have also demonstrated that CD4+ T cells expressing interleukin
1 receptor type 2 (IL-1R2) and naturally occurring regulatory T cells (nTregs), which expanded in aged 12-month-old
mice, were reduced in the thymus-grafted mice of the same age.
Conclusion: It is conceivable that the rejuvenation of systemic immune function by fetal thymus grafts contributes
not only to the activation of cellular immunity but also to the decrease of IL-1R2+ CD4+ T cells or nTregs, which
cells accelerate both age-related hearing loss (AHL) and neurodegeneration of the cochlear neurons. Further studies
on the interactions among IL-1R2 expression on CD4+ T cells, Tregs, and neuronal cells and also on the relationships
between fetal thymus grafting and the rejuvenation of systemic immunity should be designed in order to advance
towards therapeutic effects on neurosenescence, including AHL.
Keywords: Age-related hearing loss, Spiral ganglion degeneration, Fetal thymus graft, Interleukin 1 receptor type 2,
Regulatory T cell, CD4+ T cell
Background
Hearing loss has a substantial impact on quality of life
via impaired communication and can lead to social isola-
tion, poor psychosocial functioning, reduced physical
wellbeing, and unemployment [1, 2]. Age-related hearing
loss (AHL), also known as presbycusis, is a universal fea-
ture of mammalian aging and involves genetic, cellular,
and systemic-level changes in the auditory part of the
inner ear, namely, the cochlea, and the part of the
brain used for hearing, namely, the central auditory
pathway [3]. Although AHL is rapidly increasing in
incidence and the third most common chronic
medical condition of the aged, affecting about half of
the population over 75 years old [1], no strategy has
been developed for the prevention and treatment of
this neurodegenerative disease.
Recent research in gerontology has shown that
inflammaging, a state of chronic systematic inflamma-
tion associated with age, is a consequence of immu-
nosenescence, the aging of the immune system, and
contributes to the aging process and the development
of age-related disabilities and diseases including AHL
[4]. Type II diabetes and cardiovascular disease asso-
ciated with inflammaging have been identified as be-
ing linked to AHL severity [5, 6]. Verschuur et al. [4]
recently indicated that chronic inflammation represented
by the white blood cell count is strongly associated with a
worsening of AHL among community-dwelling adults
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aged over 75 years. Local inner ear immunity is part of the
overall systemic response and can induce cochlear degen-
eration and hearing loss [3, 7–9].
It is widely accepted that immune surveillance results in
immune and inflammatory responses in the central ner-
vous system (CNS) including neurons by the infiltration of
circulating immune cells and the activation of resident
cells such as microglial cells, despite the blood–brain bar-
rier [10, 11]. Interleukin (IL)-1 has been particularly impli-
cated in neurodegeneration [10] and is controlled mainly
by interleukin-1 receptor type 1 (IL-1R1) to transduce
signals, especially IL-1β and interleukin 1 receptor type 2
(IL-1R2), to diminish IL-1 without any transduction of
binding signals of IL-1 [10, 12]. IL-1 receptors interact
with IL-1 to modulate the functions of leukocytes
including CD4+ T cells, all cell types of the brain
[12], and spiral ganglion (SG) neurons [13]. Naturally
occurring regulatory T cells (nTregs) among regula-
tory T cells (Tregs) accumulate with advanced age, in
spite of thymic involution leading to a dwindling
thymic T-cell population and inducible regulatory T
cells (iTregs), and promote tissue degeneration and
senescence-associated inflammation, as well as the
disturbance of immune activation against tumors and
pathogens [14]. Depletion of Tregs was also shown to
improve neural survival after mechanical injury sig-
nificantly in an animal model [15].
Among the animal models of AHL, senescence-
associated mouse type 1 (SAMP1), a murine inbred
strain with a genetic background of AKR mice [16–18],
shows the early occurrence of thymic involution and
accelerated dysfunction of immunocompetent cells,
particularly T cells [17, 19], followed by accelerated AHL
with the degeneration of SG neurons [19].
We previously demonstrated that systematic immune
dysfunction causes AHL and SG neuron damage in the
cochlea and that retardation and prevention of the onset of
both AHL and immunosenescence are observed when the
mice are bred under immunologically clean environments
[20] and when the mice are transplanted with allogeneic
bone marrow cells [9], respectively. We have also found
that up-regulation of the expression of IL-1R2 genes in
CD4+ T cells is associated with age-related developments
of hearing loss, SG degeneration, and the dysfunction of
cellular immunity, and that the rejuvenation of recipient
immunity by the inoculation of young CD4+ T cells or a
fetal thymus graft leads to down-regulation of the genes in
CD4+ T cells and reduces these features of senescence [21].
The goals of the current study were to examine the thera-
peutic effects of fetal thymus grafts on systemic immunose-
nescence and inner ear neurosenescence once they have
already occurred and also to clarify the anti-aging mecha-
nisms of Tregs, IL-1 receptors on CD4+ T cells, and audi-
tory neurons in the cochlea using SAMP1 mice.
Results
Acceptance of syngeneic thymic tissue grafted under the
renal capsule in SAMP1 mice aged 12 months old
Because SAMP1 shows AHL from 5 months old [9], the
first thymus transplantation underwent at 6 months old.
All thymus grafts under the renal capsule of 10 SAMP1
mice (Group D) showed acceptance and preservation of
the thymus structure consisting of cortex and medulla at
12 months old, as shown in Fig. 1.
Fig. 1 Microscopic and histopathological findings of syngeneic thymic tissue grafted under the renal capsule. a Representative microscopic findings.
The graft (arrow) was observed under the renal capsule. b Representative histopathological findings. H&E staining (original magnification × 10). The
graft exhibited acceptance and preservation of the features of thymic tissue consisting of cortex (a plain arrow) and medulla (a dotted arrow). n = 10
of bilateral sides of the kidney
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Recovery from age-related development of T-cell
dysfunction after grafting of the fetal thymus
To evaluate cellular immunity, the T-cell mitogen (conca-
navalin A, Con A) response was evaluated by MTT assay.
Although untreated SAMP1 mice showed the develop-
ment of T-cell dysfunction with aging in Groups B
(6 months old) and C (12 months old), Group D, which
was 12 months old and had been transplanted with fetal
thymi twice at 6 and 8.5 months old, revealed functional
recovery with significantly higher proliferative activity
than Group B of 6 months old and no significant differ-
ences compared with Group A (2 months old) (Fig. 2).
Furthermore, to determine the major T cell population in
the spleen of the thymus-grafted mice, surface markers of
splenic T cells, gated as CD3+ cells, were analyzed by flow
cytometry. Although there was no significant difference of
the frequencies of CD8+CD3+ T cells between Groups C
and D, the frequency of CD4+CD3+ T cells in Group D
was significantly higher than those in Group C (p < 0.002)
as shown in Table 1, suggesting that the increased T cell
proliferative activity of Group D over Group C (Fig. 2)
could be the results of increased number of CD4+ T cells.
Recovery from auditory dysfunction after grafting of the
fetal thymus
The auditory functions of SAMP1 mice were examined
using auditory brain stem response (ABR) at click stim-
uli and pure tones of 4, 12, and 36 kHz. While untreated
SAMP1 mice revealed deterioration of AHL in Groups B
(6 months old) and C (12 months old) as determined by
ABR using those sounds, thymus-grafted Group D aged
12 months old revealed significant improvement of the
auditory response compared with Group B aged 6 months
old and no significant differences from the younger Group
A (2 months old) (Fig. 3).
Reduction of degeneration of SG cells of the cochlea by
the fetal thymus graft
SG cells in Groups A, B, C, and D were histopathologic-
ally examined as shown in Figs. 4a-d. Spiral ganglion
cells showed low cell density in Group B aged 6 months
old and the development of these findings in Group C
aged 12 months old as aging. On the other hand,
thymus-grafted Group D revealed no remarkable
changes in SG cells, compared with Group A aged
2 months old.
The nuclei of SG cells in the apical, middle, or basal
turns of the cochlea were also quantified to evaluate de-
generation of the auditory neurons (Fig. 4e). Untreated
mice of Groups B and C histopathologically showed age-
related developments of degeneration in SGs of the mid-
dle and basal turns. On the other hand, thymus-grafted
Group D showed significantly higher density of the
nuclei than Group B in all turns and did not reveal a sig-
nificant difference from Group A aged 2 months old in
the apical and basal turns.
Fetal thymus graft suppresses the age-related increase in
expression of IL-1R2 and FR4 on splenic CD4+ T cells and
does not change regulation of IL-1R1
The next step was to examine the effect of the fatal thy-
mus graft on expression of Tregs and IL-1 receptors on
CD4+ T cells in SAMP1 mice of our accelerated AHL
model. Flow cytometric analysis indicated the setting
gates (squares of R1-R3) for CD121a (IL-1R1)+CD4+
cells, CD121b (IL-1R2)+CD4+ cells, and folate receptor 4
(FR4)hiCD4+ cells as nTregs (Fig. 5). This FR4 is a
Fig. 2 Therapeutic effects of the fetal thymus graft on cellular immunity.
To evaluate cellular immunity, the T-cell mitogen (Con A) response was
evaluated by MTT assay. Absorbance at 570 nm was determined on a
scanning multiwell spectrophotometer. Data are shown at stimulation
index (SI), calculated as the ratio of Con A-stimulated to unstimulated
T cells. Age-related decline of T-cell functions observed from untreated
SAMP1 mice aged 6 months (Group B) to those aged 12 months old
(Group C) (*p< 0.05) was recovered in thymus-grafted SAMP1 mice aged
12 months old (Group D, **p< 0.001). There was no significant difference
in the Con A responses between untreated SAMP1 aged 2 months old
(Group A) and thymus-grafted Group D mice. Experiments were run in
triplicate. NS: no significance. n= 3–4/group (mean ± SD)
Table 1 Evaluation of the major T cell population
Groups CD4+CD3+ (%) CD8+CD3+ (%)
C (untreated mice of 12 months
old)
10.4 ± 0.08 3.85 ± 0.21
D (thymus-grafted mice of 12
months old)
12.9 ± 0.26* 3.86 ± 0.36a
To evaluate the major T cell population, CD4+CD3+ T cells and CD8+CD3+ T
cells were analyzed by flow cytometry after the staining with FITC-anti-mouse
CD4 mAb plus PE-anti-mouse CD3 mAb, or FITC-anti-mouse CD8 mAb plus
PE-anti-mouse CD3 mAb
*The frequency of CD4+CD3+T cells in Group D was significantly higher than
those in Group C (p < 0.002)
aThere was no significant difference of the frequencies of CD8+ CD3+T cells
between Groups C and D. All experiments were in triplicate
n = 3/group (mean ± SD)
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functionally essential molecule for Tregs and is constitu-
tively highly expressed on nTregs [22].
Table 2 shows the data from the squares and indicates
that IL-1R1 expression on CD4+ cells has no difference
between any groups without any influence of aging or
thymus graft. Although there was no significant differ-
ence between Group B aged 6 months old and Group C
aged 12 months old in terms of age-related progression
in the expression of IL-1R2 and FR4 on CD4+cells,
Group B showed significant up-regulation of CD121b
and FR4 on CD4+ cells in comparison with Group A
aged 2 months old, via aging. Group D aged 12 months
old with thymus graft still showed significant differences
from Group A, indicating that the graft could not reveal
sufficient effect to down-regulate those surface antigens
to the level of Group A; however, Group D showed sig-
nificant reduction of the receptors of CD121b and FR4
compared with Group B, as a result of fetal thymus
transplantation.
Discussion
Although cochlear implants can effectively replace the
mechanosensory transduction function of lost hair cells
by providing direct electrical stimulation of SG neurons
in the cochlea, this technique can only be successful
when sufficient SG neurons remain [23]. Thus, there is
an urgent need to analyze the mechanisms of age-
related SG neuron loss with the global increase in the
size of the elderly population.
SAMP1 mice used in the current study show acceler-
ated senescence including degeneration of SG neurons,
AHL, thymic involution, and cellular immune dysfunc-
tion, as well as alopecia, spiral curvature, and shortened
lifespan [16, 17, 19]. We previously demonstrated that
these mice do not show AHL upon the inoculations of
CD4+ T cells from a syngeneic donor aged 2 months old
twice at a two-month interval or can avoid AHL and SG
neuron loss by syngeneic fetal thymus grafting at
2 months old (before the onset of AHL) [21]. These re-
sults encouraged us to design the present experiment
that attempted to treat the immunosenescence, AHL,
and cochlear pathology of SAMP1 mice aged 6 months
old (after the onset of AHL) and to obtain insight into
the development of Tregs and IL-1 receptors on CD4+ T
cells, which had been reported to have a relationship to
CNS degeneration [10, 12–15].
Figure 1 shows that fetal thymus grafts were accepted,
thereby preserving the thymus structure, by syngeneic
recipients under the renal capsule, where experimental
transplantation of organs is often performed because of
the rich vascularity [24]. The age-related developments
of T-cell dysfunction, hearing loss, and SG neuron de-
generation in the mice aged 6 months old were recov-
ered from at 12 months old after the thymus transplants
had been applied twice (Figs. 2, 3 and 4). We previously
performed preliminary experiments using a group aged
12 months of sham surgery without fetal thymus grafts
and found that there was no difference of T-cell func-
tions and acoustic functions between the sham group
and the control group of the same age (data not shown).
Thus, cellular supply from grafts of the thymus, which
supports hematopoietic progenitor cells migrating from
bone marrow and outputs naïve T cells into the systemic
immune system [25], enabled recovery from both sys-
temic immunosenescence and cochlear neurosenescence.
On the other hand, it is not clear in the current study
Fig. 3 Therapeutic effects of the fetal thymus graft on age-related hearing loss. The auditory functions of SAMP1 mice were examined using ABR
at click stimuli and pure tones of 4, 12, and 36 kHz. The development of AHL observed in untreated SAMP1 mice (*p < 0.05–0.005 between Group B
aged 6 months old and Group C aged 12 months old) was canceled in thymus-grafted Group D aged 12 months old (**p < 0.01–0.0005 between
Groups B and D). The thresholds of Group D showed no significant difference from those of Group A consisting of 2-month-old SAMP1 mice (p > 0.05
between Groups A and D). NS: no significance. n = 10/group (mean ± SD)
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whether SG neurons, which once showed decline of cell
density at 6 month old, increased the number equivalent
to that in the mice in 2 months old after fetal thymus
transplantation. Because SAMP1 shows hearing loss at
5 months old [9], we have grafted the thymus at 6 (and
8.5) months old. This animal strain shows hearing loss
at first, and then reveals progression of neuron loss in
SG until 12–14 months old [6]. Six months old is, there-
fore, considered to be an early phase of degeneration.
There may be considered two explanations for recov-
ery of cell density in SG as well as auditory functions
comparing thymus-grafted mice aged 12 months with
control mice aged 6 months: 1) the neurons once de-
creased the number at 6 months old due to cell
death, however, regenerated and boosted it according
to local increase of neurotrophic factors in response
to recovery of cellular immunity after thymus graft,
and 2) SG started to show dysfunction and decrease
Fig. 4 Anti-neurodegenerative effects of the fetal thymus graft on SG cells of the cochlea. SG cells in Groups A (a), B (b), C (c), and D (d) were
histopathologically examined. Representative findings. H&E staining (original magnification x100). Several cells showed degeneration in the spiral
ganglion of Group B aged 6 months old and the development of these findings in Group C aged 12 months old as aging. On the other hand,
thymus-grafted Group D revealed no remarkable changes in SG cells, compared with Group A aged 2 months old. e) To evaluate degeneration of
the auditory neurons, the nuclei of SG cells in the apical, middle, or basal turns of the cochlea were quantified. Although no significant difference of
density of the nuclei/10,000 μm2 was observed between Group B aged 6 months old and Group C aged 12 months old at the apical
turn (p = 0.065), age-related devastation of the density of SGs between Groups B and C was found in the other turns (p < 0.005–0.0005),
and significant recovery of the density in thymus-grafted Group D in comparison with that in Group B at all turns (p < 0.01–0.00005) was
observed. The significant recovery of neurodegeneration in Group D was insufficient to reach the level of Group A in the middle turn
(p = 0.033); however, no significant difference in comparison with Group A was observed in any other turns (p > 0.05). NS: no significance.
n = 5 for Groups A-C and 10 for Group D (mean ± SD)
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of cell density at 6 months due to cell expansion as a
consequence of edema and/or accumulation of metab-
olite in the cytoplasm as a preparatory stage for de-
generation, however, survived, reactivated, and shrank
the cells by immunological improvement after thymus
graft. Further studies are needed to elucidate the
effects of cellular immunity modified by the fetal thy-
mus graft on neuronal anti-ageing system. This rela-
tionship between systemic immunity and the inner
ear is reminiscent of prior findings in our laboratory
that revealed that allogeneic transplantation to renew the
host immunity by an allogeneic donor treated auto-
immune hearing loss and lupus nephritis in MRL/Mp-lpr/
lpr mice, a murine model of autoimmune sensorineural
hearing loss (SNHL) and systematic lupus erythematosus
(SLE) [26].
Rejuvenation of the thymus leads to reconstitution of
cellular immunity with functions as good as young cells
and better than those of aged mice and humans [27]. On
the other hand, thymectomy induces an imbalance be-
tween lymphocytes, macrophages, and cytokines, which
induces neurotransmitter and neuroendocrine changes
through the blood–brain barrier, and memory disturbance
in CNS [28]. Both acute and chronic systemic inflamma-
tion is associated with an increase in cognitive decline in
Alzheimer’s disease [11]. All neuronal cells and locally in-
vading leukocytes including T cells and macrophages can
express IL-1 and IL-1R1, which enables them to respond
to IL-1 in an autocrine and paracrine manner [10]. There-
fore, our next step was to examine surface markers of
CD4 T cells that are the center to manage cellular immun-
ity and the relationship with CNS. An increase of IL-1R1
expression and IL-1 production has been reported in aged
rodents, suggesting that CD4+ T cells from the animals
are highly responsive to IL-1R1 stimulation and prepared
to differentiate into Th17 cells, which is closely linked to
autoimmune diseases [29]. The results, however, indicated
that IL-1R1 on CD4+ T cells did not show any change in
regulation as a consequence of aging or thymus grafting
(Fig. 5 and Table 2). We previously indicated that there
are no autoimmune mechanisms in AHL in SAMP1 mice
because prednisolone administration had no preventive
effect against this cochlear dysfunction in the mice [20].
On the other hand, our data demonstrated that the ex-
pression of IL-1R2 on the cells was increased by aging
and decreased by thymus grafting. IL-1R2 serves as a
decoy receptor binding to IL-1, but does not induce
signal transduction due to the lack of an intracellular
domain [29]. IL-1 receptor antagonist (IL-1Ra) also sup-
presses the function of IL-1 as a proinflammatory cyto-
kine to prevent the binding of IL-1 and restricts the
recruitment of IL-1R accessory protein (IL-1RAcp) [30].
Fig. 5 Gating for IL-1R1, IL-1R2, and FR4 on CD4+ T cells. Surface markers of IL-1R1 (a), IL-1R2 (b), and FR4 (c) on CD4+ T cells were examined
using FITC-conjugated anti-mouse CD4 cell mAb, PE-conjugated anti-mouse CD121a (IL-1R1) mAb, PE-conjugated anti-mouse CD121b (IL-1R2)
mAb, and biotin-conjugated anti-mouse FR4 (nTreg) mAb plus streptavidin-RED670 with flow cytometry. a) Square R1, b) square R2, and c) square
R3 include CD121a+ CD4+ cells, CD121b+ CD4+ cells, and FR4hi CD4+ cells, respectively
Table 2 Down-regulation of IL-1R2 and FR4 on splenic CD4+ T
cells by fetal thvmus graft
Groups Square R1a Square R2 Square R3
CD121a+
cells (%)
CD121b cells (%) FR4 hi cells (%)
on CD4+ cells* on CD4+ cells on CD4+ cells
A, 2 months old 0.46 ± 0.07 0.33 ± 0.08 11.02 ± 0.81
B, 6 months old 0.39 ± 0.14 0.83 ± 0.21** 23.52 ± 0.80****
C, 12 months old 0.46 ± 0.18 1.07 ± 0.13 22.10 ± 1.63
D, 12 months old 0.58 ± 0.28 0.57 ± 0.03*** 12.85 ± 0.54*****
Thymus-grafted
aSquares of R1-R3 are shown in Fig. 5
*p > 0.05 between any groups
**p < 0005 between Groups A and B. p < 0.01 between Groups B and D.
p > 0.05 between Groups B and C
***p < 0.005 between Groups A and D
****p < 0.005 between Groups A and B. p < 0.005 between Groups B and D.
p > 0.05 between Groups B and C
*****p < 0.01 between Groups A and D. All experiments were run in triplicate
n = 3–4/group (mean ± SD)
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Protective and toxic effects of IL-1 are associated with
the exogenous and endogenous concentrations of IL-1
and the localized nature of its actions [10]. The local
secretion of IL-1Ra in the cochlea using an adenovirus
vector and IL-1Ra cDNA promotes the degeneration of
SG cells [13]. Sustained transgenic IL-1 over-expression,
as well as in vitro exposure to IL-1, contributes to a re-
duction in amyloid pathology, mediated by enhancement
of microglia-dependent plaque degradation, with no evi-
dence for IL-1-associated apoptosis of neurons [31].
After a CNS injury, T cells nonselectively migrate to the
site of injury, suggesting that homing T cells, which en-
counter their relevant antigens at the lesion site, are the
ones that contribute to the repair. Such T cells become
locally activated to produce cytokines including IL-1 and
neurotrophic factors, which are capable of affecting the
activity of resident microglia and hence the fate of
threatened neurons [14]. Therefore, the increase of
expression of IL-1R2 on CD4+ T cells in the current
study of AHL may be involved in age-related disability,
which locally leads to the lack of IL-1 signal transduc-
tion, causing cell death.
nTregs express CD4, CD25, and Foxp3 and accumu-
late with age via thymic involution, while iTreg numbers
decrease. The increase of Treg activity generally contrib-
utes to autoimmunity in the young and to an impaired
anti-tumor response, declining anti-microbial immune
responses, and the development of tissue degeneration
in the elderly [14]. Yamaguchi et al. [22] reported FR4 is
a functionally essential molecule for Tregs and is consti-
tutively highly expressed on nTregs; they also demon-
strated that the blockage of FR4 sufficed to deplete
CD25+CD4+ nTregs and that the transfer of FR4hi cell-
depleted T-cell suspensions induced autoimmune dis-
ease in nude mice that had rejected tumors. In addition,
anti-FR4 mAb treatments prevented the development of
methylcholanthrene (MCA)-induced sarcoma [32]. We
utilized this FR4 as an nTreg marker in the current study
and found that the FR4nhi Treg population expanded in
the aged mice and shrank in the thymus-grafted mice.
Causal links between increased Treg numbers and the
incidence of neurodegenerative disease have been sug-
gested since neuron survival was found to be higher
in the absence of Tregs in a mouse model of optic
nerve injury [15].
The present findings raise the question, which must
be answered by subsequent experiments, of which
cells are mainly associated with SG degeneration, IL-
1R2+ CD4+ T cells (non-Tregs), Tregs, or IL-1R2+
Tregs. While there is no significant difference in sup-
pressive capacity between IL-1+ Tregs and IL-1R1−
Tregs, Tregs expressing IL-1R2 neutralize IL-1β as a
result of TCR activation [33]. Although it is still un-
clear whether the suppressive effects of activated
Tregs contribute to the action of expressed IL-IR2 or the
original functions of the Tregs themselves, IL-1R2+ CD4+
T cells and activated Tregs might be new targets for thera-
peutic intervention in IL-1-mediated neurodegenerative
diseases.
To our knowledge, this study is the first to show
that syngeneic transplantation of the thymus can be
used to treat AHL and regulate both IL-1R2+ CD4+
T cells and Tregs.
We evaluated frequencies of splenic CD4+ and CD8+
T cells of the untreated and the thymus-grafted mice,
and the number of CD4+ T cells in the grafted mice was
more than that of the control mice (Table 1) suggesting
that the CD4+ T cells were supplied from the grafted
thymus and probably contributed to the immune reju-
venation leading to the recovery of Con A responses as
shown in Fig. 2. On the other hand, it was not estab-
lished in the present study with syngeneic thymus grafts
whether the CD4+ T cells derived from the recipient
bone marrow cells and matured through the thymus
grafts or from fetal thymus grafts where donor progeni-
tor cells proliferated and seeded recipient peripheral
tissues. Because we previously demonstrated that donor
immunocompetent cells systemically appeared in SAMP1
mice that had been transplanted allogeneic bone marrow
cells at 2 months old before the start of thymic involution,
it is likely that the grafted thymus supplied recipient CD4+
T cells in the current study.
Recent studies to analyze the development of hearing
loss focus not only on the disability in the auditory
organ, but also systemic functions affected by metabolic
changes, hormones, diet, and the immune system [34].
Our current study using a mouse model suggests at least
three strategies to prevent AHL: i) IL-1R2− CD4+ T cells
or non-Tregs collected at a young age would be pre-
served and then inoculated several times into autologous
recipients that were previously the donors of the cells
and then have shown AHL. ii) The use of thymic epithe-
lial cells differentiated from autologous pluripotent stem
cells [35]. Grafting of these cells under the renal capsule
[24] or injection of these cells into the spleen or the
peritoneal cavity [36] might contribute to the treatment
of AHL and the rejuvenation of the recipients to de-
crease IL-1R2+ CD4+ T cells and Tregs. iii) Finally, the
targeting of IL-1R2+ CD4+ T cells and Tregs with anti-
bodies to treat neurodegeneration could be applied.
Conclusion
We found in an AHL animal model that the increase of
IL-1R2+ CD4+ T cells and nTregs was associated with
the age-related development of T-cell dysfunction and
the degeneration of SG in the cochlea, and that fetal thy-
mus grafts treated AHL and reduced neurodegeneration
and both IL-1R2+ CD4+ T cells and nTregs. Therefore, it
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is conceivable that the rejuvenation of systemic immune
function by fetal thymus grafts contributes to the activa-
tion of cellular immunity and to the decrease of IL-1R2+
CD4+ T cells or nTregs, which cause AHL as a conse-
quence of neurodegeneration of the cochlear neurons.
Further studies on the interactions among IL-1R2 ex-
pression on CD4+ T cells, Tregs, and neuronal cells and
also on the relationship between the fetal thymus graft
and the rejuvenation of systemic immunity should be
designed to advance towards therapeutic effects on
neurosenescence, including AHL.
Methods
Animals and experimental design
SAMP1 were purchased from SLC (Shizuoka, Japan) and
maintained under specific pathogen-free conditions in
our animal facilities. The care and use of the mice re-
ported in this study were approved by a grant applica-
tion agency [Grants-in-Aid for Scientific Research
(21592170 and 10232638) from the Ministry of Educa-
tion, Science, Sports and Culture].
We divided SAMP1 mice into 4 groups consisting of
2-month-old SAMP1 mice as Group A, 6-month-old
SAMP1 mice as Group B, 12-month-old SAMP1 mice
as Group C, and the SAMP1 mice (12 months old)
grafted with syngeneic fetal thymus (gestational age of
18–19 days) under the capsule of the left kidney at
6 months old and of the right kidney at 8.5 months old
as Group D. These mice were examined for T-cell func-
tions, acoustic functions, and the pathology of the coch-
lea. CD4+ T cells were also analyzed by flow cytometry
for their cell surface antigens, especially IL-1 receptors
and FR4, which are highly expressed on Foxp3+CD25
+CD4+ nTregs [22].
MTT, 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide, assay for T-cell function
To examine cellular immune functions, the proliferative
responses of splenic T cells were evaluated using the
MTT assay in accordance with the manufacturer’s in-
structions (MTT cell proliferation assay kit; Cayman
Chemical Co., Ann Arbor, MI, USA). This assay is based
on the capacity of mitochondrial dehydrogenase en-
zymes in viable cells to convert the yellow water-soluble
substrate, MTT, into a dark blue formazan product,
which is insoluble in water. A solubilization solution is
then added to dissolve the insoluble purple formazan
product into a colored solution, which is quantified by
its absorbance. Briefly, cells were seeded at a density of
1x105 cells/well in triplicate in 96-well plates with Con
A (2.5 mg/ml; Calchem-Behring Corp., San Diego, CA)
T-cell mitogen for 2 days, followed by adding an aliquot
of MTT solution at 0.5 mg/ml to each well and incubat-
ing the plates for 4 h at 37 °C. The medium was then
discarded, and the formazan blue formed in the cells
was dissolved in dimethyl sulfoxide (DMSO). Absorb-
ance at 570 nm was determined on a scanning multiwell
spectrophotometer. Data are expressed at stimulation
index (SI), calculated as the mean reading of triplicate
wells of antigen (Con A)-stimulated T cells divided by
the mean reading of triplicate wells from unstimulated
(negative control) wells.
Analysis of the major T cell population
Surface markers of CD4, CD8, and CD3 (BD Phar-
mingen, San Diego, CA) were examined with FACS-
can (Becton Dickinson & Co.) using FITC-conjugated
rat anti-mouse CD4 mAb, FITC-conjugated rat anti-
mouse CD8 mAb, and PE-conjugated rat anti-mouse CD3
mAb. All experiments were run in triplicate (n = 3/group).
Auditory response
The auditory function of the mice was evaluated by
means of ABR, as described previously (Iwai et al.,
2003). ABR is an evoked potential measurement of the
auditory activity of the cochlea, auditory nerve, and cen-
tral auditory pathway in the brainstem. Prior to testing,
the mice were anesthetized with sodium pentobarbital
(60 mg/kg, i.p.) and atropine sulfate (0.5 mg/kg, i.p.).
Otoscopic examinations revealed normal tympanic
membranes in all mice. Needle electrodes were inserted
into the occiput, vertex, and hindpaw (ground). Click
stimuli produced by 2 V pulses of alternating polarity of
100 msecond duration and pure tone stimuli of 4 kHz,
12 kHz, and 36 kHz presented for a duration of 5 mse-
conds with a 1 msecond rise/fall time at a rate of 10 per
second were generated using the SigGenRP software
package (Tucker-Devis Technologies, Alachua, FL).
These sound stimuli were delivered to the left external
auditory meatus in a closed acoustic system. The average
responses from 1,000 sound stimuli were obtained for
each auditory stimulus by reducing the sound inten-
sity until the threshold. The thresholds were verified
at least twice and defined as the lowest intensity pro-
ducing a clearly visible first wave peak, the origin of
which is closely connected to spiral ganglion neurons
[37] (n = 10/group).
Histopathology
After auditory examination and splenectomy for the
mitogen response and flow cytometric analysis, the mice
were subjected to intracardiac perfusion with saline
followed by 4 % paraformaldehyde phosphate buffer
solution and decalcification at 4 °C in 5 % buffered
EDTA for 7 days. The temporal bones were sectioned at
4 μm horizontally to the long axis of the cochlea and
stained with hematoxylin and eosin (H&E). The sections
were randomly selected from these mid-modiolar
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sections for each animal, and the nuclei of SG neurons
in the apical, middle, or basal turn of the cochlea were
quantified as previously described [9, 38]. The absolute
density value was normalized for 10,000 μm2 (n = 5 for
Groups A-C and 10 for Group D). The grafted tissues
of the fetal thymus under the renal capsule of Group
D were also evaluated for graft acceptance after stain-
ing with H&E (n = 10).
Analysis of expression of IL-1R1, IL-1R2, and FR4 on
splenic CD4+ T cells
Surface markers of IL-1R1 and IL-1R2 on splenic CD4+
T cells were examined with FACScan using FITC-
conjugated rat anti-mouse CD4 mAb, PE-conjugated rat
anti-mouse IL-1R1 (CD121a) mAb (BD Pharmingen),
PE-conjugated rat anti-mouse IL-1R2 (CD121b) mAb
(BD Pharmingen), and biotin-conjugated rat anti-mouse
FR4 (natural Treg) mAb (Reprocell Co., Tokyo, Japan) plus
streptoavidin-Red670 conjugate (SA-RED670; BIBCO,
Grand Island, NY). All experiments were run in triplicate
(n = 3-4/group).
Statistical analysis
Data are presented as the mean ± SD. Statistical ana-
lyses were performed by Student’s t-test and ANOVA
(StatMateV, Atoms Co. Tokyo, Japan). Statistical sig-
nificance was accepted at p < 0.05.
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